This chemical is primarily utilized in the field of targeted drug delivery, particularly in cancer therapy. It is designed to improve the efficacy and reduce the side effects of chemotherapy. The compound is engineered to release the active drug, SN38, which is a potent topoisomerase I inhibitor, specifically at the tumor site. This targeted approach minimizes damage to healthy tissues and enhances the overall therapeutic outcome. It is often incorporated into nanoparticle-based delivery systems or conjugated with antibodies to achieve precise targeting. Its application is especially significant in treating colorectal, lung, and pancreatic cancers, where traditional chemotherapy methods have limitations.